Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
Viral load one month after starting HAART predicts who will be detectable after six months treatment

Measuring viral load a month after starting highly-active antiretroviral therapy (HAART) can strongly predict which individuals will have a viral below 50 copies/ml after six

Published
03 September 2004
By
Michael Carter
Drug-resistant HIV acquired during infection may persist for up to seven years

HIV-positive patients infected with a drug-resistant strain of the virus may not show a reversion to the wild-type strain for up to seven years after

Published
12 August 2004
By
Christopher Gadd
Second major study shows rise in drug resistance is not increasing AIDS or death risk

The development of resistance to antiretroviral drugs does not increase the risk of HIV disease progression or death, according to an American study published in

Published
05 August 2004
By
Liz Highleyman
Drug resistant HIV present in quarter of gay men newly infected with HIV in England in 2002

Over 27% of gay men in England, Wales and Northern Ireland in 2002 with recently acquired HIV had been infected with a drug-resistant strain of

Published
14 July 2004
By
Michael Carter
HIV Drug Resistance Workshop: new concepts for the clinician

Researchers from Cleveland in a study of nelfinavir (NFV) and its primary mutation D30N which has been shown to reduce replicative competence posed a question

Published
29 June 2004
By
Yasmin Halima
HIV Drug Resistance Workshop: population surveys of resistance

Many guidelines now include recommendation for resistance testing before patients begin antiretroviral therapy where the prevalence of population resistance is known to be 10% or

Published
29 June 2004
By
Yasmin Halima
HIV Drug Resistance Workshop: prevention of mother to child transmission

A number of studies of the prevention of mother to child transmission (PMTCT) now appear to point to an ominous conclusion: single-dose nevirapine (NVP) may

Published
29 June 2004
By
Yasmin Halima
HIV Drug Resistance Workshop: key take home messages

Each year this distinguished workshop reports on the progress in basic science in HIV drug resistance including profiles of new agents, illuminating mechanisms of resistance

Published
29 June 2004
By
Yasmin Halima
HIV Drug Resistance Workshop: Non-B HIV subtypes

The mapping of resistance pathways in non-B patients is becoming increasingly important for two main reasons. Firstly, migration patterns in Europe have resulted in a

Published
29 June 2004
By
Yasmin Halima
HIV Drug Resistance Workshop: entry and attachment inhibitors

New arsenals of compounds that focus on extracellular targets are currently under development – some further along the development pipeline than others. Even those

Published
29 June 2004
By
Yasmin Halima

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.